Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

What Was Tested

This registered phase 4 trial tested Semaglutide.

It had two arms (groups): Catheter ablation for atrial fibrillation plus semaglutide (experimental) and Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy (no intervention).

Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy (standard therapy).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 240 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 18-80 years. Symptomatic paroxysmal or persistent AF eligible for first-time catheter ablation. Body mass index ≥30 kg/m or body mass index ≥28 kg/m plus ≥1 weight-related comorbidity. No prior treatment with glucacon-like peptide-1 receptor agonists.

The full record lists 4 inclusion and 16 exclusion criteria; among the exclusions: current use of glucacon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors or use within the last 90 days prior to screening; current antiobesity medication use or use within the last 90 days prior to screening; A self-reported change in body weight of \>5 kg within 30 days before screening.

How the Study Was Run

The set-up was randomized, parallel-group and single-blind.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

The Semaglutide group and the comparison group ran side by side rather than switching.

In this single-blind Semaglutide study one party knew the assignments and the other did not.

Those kept unaware of assignments: outcomes assessor.

It started in 2026-10 with completion listed for 2029-04.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period) (time frame: 12 months).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 240 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.